Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

March-April, 2026
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Quality / GMP

Zydus receives US FDA approval for Tavaborole Topical Solution, 5%

Zydus receives US FDA approval for Tavaborole Topical Solution, 5% Zydus Lifesciences Limit has received final approval from the United States Food and Drug Administration (US FDA) to manufacture and market Tavaborole Topical Solution, 5 per cent. Tavaborole topical solution is indicated to treat fungal toenail infections (infections that may cause nail discolouration, splitting, or pain). The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad.
Read more on:
USFDA Zydus Lifesciences
More news about: quality / gmp | Published by Sudeep Soparkar | April - 13 - 2023 | 860

Last news about this category

Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS
Junshi Biosciences Secures China Approval for Toripalimab Combination Therapy in Advanced Urothelial Cancer Junshi Biosciences Secures China Approval for Toripalimab Combination Therapy in Advanced Urothelial Cancer
Qihan Biotech Secures US FDA IND Clearance for Next-Generation Universal CAR-T Therapy QT-019C Qihan Biotech Secures US FDA IND Clearance for Next-Generation Universal CAR-T Therapy QT-019C
Bayer Receives FDA Priority Review for Kerendia in Type 1 Diabetes-Related Kidney Disease Bayer Receives FDA Priority Review for Kerendia in Type 1 Diabetes-Related Kidney Disease
Sunrise Air Receives US FDA Clearance, Expanding Access to At-Home Sleep Apnoea Diagnosis Sunrise Air Receives US FDA Clearance, Expanding Access to At-Home Sleep Apnoea Diagnosis
US FDA Approves First Golimumab Biosimilars Immgolis and Immgolis Intri for Rheumatoid Arthritis and Ulcerative Colitis US FDA Approves First Golimumab Biosimilars Immgolis and Immgolis Intri for Rheumatoid Arthritis and Ulcerative Colitis
Racura Oncology Advances RC220 to Higher Dose Level in Phase 1 CPACS Cancer Trial Racura Oncology Advances RC220 to Higher Dose Level in Phase 1 CPACS Cancer Trial
Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan
Lundbeck Secures Orphan Drug Designation in Japan for Asedebart Targeting Rare Endocrine Disorders Lundbeck Secures Orphan Drug Designation in Japan for Asedebart Targeting Rare Endocrine Disorders
FDA Clears IND Application for Chengdu Origen's Gene Therapy Targeting Hypertrophic Cardiomyopathy FDA Clears IND Application for Chengdu Origen's Gene Therapy Targeting Hypertrophic Cardiomyopathy
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy